1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Hanmi/Aptose’s AML Contender Shows Early Promise

Oral Myeloid Kinome Inhibitor Set For Expansion Trials

 
• By Jung Won Shin

Hanmi Pharmaceutical’s hopes for AML drug candidate HM43239, licensed out to Aptose Biosciences, are rising amid accumulating clinical data that appear to put the oral myeloid kinome inhibitor on the right track to registrational studies.

AML
Hanmi’s AML Candidate Nears Registrational Studies • Source: Shutterstock

A series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd.’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are moving the once-daily, oral myeloid kinome inhibitor closer to registrational studies.

The drug is currently in an international Phase I/II trial in 34 patients with relapsed or refractory (R/R) AML who...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

More from Therapy Areas

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.